Pay in 4 interest-free payments of $7.32 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
By describing the biologics that have been developed in the cardiovascular field over the past 4 years, which have entered the clinical area and are therefore expected to soon reach human application, this review aims to offer insights into how biologics could transform cardiovascular care, ultimately facilitating the successful translation of biologic therapies from the bench to the bedside
2020 Apr;9(4):27988
Metabolic support
GLP-1R agonists were developed as long-acting therapeutic agents to overcome the short half-life of endogenous GLP-1, namely Semaglutide (Ozempic, Wegovy, Rybelsus)
WHY LOW-INTENSITY CARDIO IS ONE OF THE MOST SUSTAINABLE FAT LOSS TOOLS HOW HIGH-INTENSITY CARDIO CAN INTERFERE WITH RECOVERY & PERFORMANCE DO ORAL CONTRACEPTIVES IMPACT MUSCLE GROWTH & STRENGTH
3,507 GLP-1RAs reduce liver fat accumulation by activating AMPK, which inhibits fatty acid synthesis enzymes and promotes fatty acid -oxidation, thus diminishing lipid droplet accumulation in hepatocytes
